A randomized trial of cyclophosphamide, doxorubicin, and cisplatin with or without bacillus Calmette-Guerin in patients with suboptimal stage III and IV ovarian cancer: A gynecologic oncology group study

Creasman, William T.; Omura, George; Brady, Maureen; Yordan, Edgardo; Disaia, P; Beecham, Jackson B.

doi:10.1016/0020-7292(91)90782-z

Cited by 3 publications

(6 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Regarding histology, the mucinous subtype is generally associated with a good clinical outcome in early ovarian cancer (19,26) but with a poor survival in advanced disease, probably due to its chemoresistance (22,31,32) . All authors agree (13,17,18,33) that early stage patients with clear cell tumors do worse than those with other subtypes.…”

Section: Discussionmentioning

confidence: 99%

Analysis of failures in patients with stage I ovarian cancer: an Italian multicenter study

Gadducci

Sartori

Maggino

et al. 1997

International Journal of Gynecological Cancer

View full text Add to dashboard Cite

Gadducci A, Sartori E, Maggino T, Zola P, Landoni F, Fanucchi A, Stegher C, Alessi C, Buttitta F, Bergamino C. Analysis of failures in patients with stage I ovarian cancer: An Italian multicenter study. Int J Gynecol Cancer 1997; 7: 445-450.The objective of this retrospective multicenter study was to assess the rates, times, sites, and risk factors for recurrences in 224 patients with surgical stage I ovarian cancer. Postoperative adjuvant treatment was given to 153 of these patients. One hundred and eighty-two (81.3%) patients are currently alive with no clinical evidence of disease after a median time of 84 months (range, 4-191 months) from surgery, whereas 39 (17.4%) developed recurrent disease after a median time of 29 months (range, 5-112 months). The relapse involved the pelvis in 21 (53.8%) cases, abdomen in 19 (48.7%), pelvic and/or para-aortic lymph nodes in 5 (12.8%), and distant sites in 5 (12.8%). The risk of recurrence was significantly related to FIGO substage (P < 0.0001) and tumor grade (P < 0.0001), but not to histological subtype. However, the recurrence rate was lower in mucinous carcinomas (6/52, 11.5%) and higher in clear cell carcinomas (5/14, 35.7%). By log-rank test the disease-free survival was significantly related to FIGO substage (P = 0.0006) and grade (P = 0.0001). Cox proportional hazard model showed that grade was the only independent prognostic variable for disease-free survival, with a risk ratio for relapse of 2.831 (95% CI, 1.120-6.624) for grade 2 and 7.725 (95% CI, 3.290-18.140) for grade 3, compared to grade 1. In conclusion, tumor grade is the strongest predictor of recurrence in stage I ovarian cancer.

show abstract

Section: Discussionmentioning

confidence: 99%

Analysis of failures in patients with stage I ovarian cancer: an Italian multicenter study

Gadducci

Sartori

Maggino

et al. 1997

International Journal of Gynecological Cancer

View full text Add to dashboard Cite

show abstract

“…Young age is also related to a higher incidence of borderline and low malignancy‐potential tumors ( 18 ) . Other factors such as initial tumor size ( 9 ) , ascites ( 8 ) , hypoalbuminemia ( 11 ) , use of cisplatin ( 10 ) , and dose intensity of chemotherapy ( 10 ) have been shown to be predictive in one study.…”

Section: Evaluation Of Prognostic Variablesmentioning

confidence: 98%

“…Performance status was demonstrated to have independent predictive value in only one ( 11 ) of the three multivariate studies analyzed ( 4 , 9 ) . Stage has been studied in eight trials and has shown predictive value in four ( 5 , 6 , 8 , 10 ) .…”

Section: Evaluation Of Prognostic Variablesmentioning

confidence: 99%

“…In ovarian cancer, multiple prognostic factors have been identified. Conventional factors such as stage, grade, residual disease, and performance status have been extensively analysed in several multivariate studies ( 3 –11 ) . Other factors (histology, morphometrics, initial volume of disease, age, and presence of ascites) related to the traditional ones have also been investigated.…”

Section: Evaluation Of Prognostic Variablesmentioning

confidence: 99%

“…Age has generated prognostic interest in two of the eight studies that have used the multivariate technique ( 6 , 9 ) . Disease stage tends to increase with age due to late diagnosis, such that the mean age of patients with stage I–II disease is 7–12 years younger than the mean age of patients with stage III–IV disease.…”

Section: Evaluation Of Prognostic Variablesmentioning

confidence: 99%

See 2 more Smart Citations

Prognostic factors in advanced ovarian cancer

CERVANTES

1997

Int J Gynecol Cancer

View full text Add to dashboard Cite

show abstract

The Gynecologic Oncology Group experience in ovarian cancer

1999

Self Cite

View full text Add to dashboard Cite

Trials performed in the past 15 years by the Gynecologic Oncology Group identified as optimal a platinum/taxane combination as the backbone to treat chemonaive ovarian cancer. Comparison to a triplet adding a third drug to the backbone is least likely to significantly improve outcome, however, of the drugs currently available for addition ; doxil, etoposide, gemcitabine, and topotecan; none appears to be any better or worse than was paclitaxel a decade ago. An approach more likely to improve outcome would

show abstract

A randomized trial of cyclophosphamide, doxorubicin, and cisplatin with or without bacillus Calmette-Guerin in patients with suboptimal stage III and IV ovarian cancer: A gynecologic oncology group study

Cited by 3 publications

References 0 publications

Analysis of failures in patients with stage I ovarian cancer: an Italian multicenter study

Analysis of failures in patients with stage I ovarian cancer: an Italian multicenter study

Prognostic factors in advanced ovarian cancer

The Gynecologic Oncology Group experience in ovarian cancer

Contact Info

Product

Resources

About